PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in ...

Dogs that have oral squamous cell carcinomas often need surgery that disfigures their jaws and lower their quality of ...

Dr Toral Vaidya, a New York City based board certified dermatologist, recently shared signs and symptoms of skin cancer she ...

Dr Toral Vaidya, a dermatologist based in New York City, has shared the different types of skin cancer there are and the ...

The following is a summary of “St Andrews Referral Delay in Skin Cancer (StARDISC): A study of keratinocyte skin cancer time ...

Skin cancer is the most common cancer in the U.S., with risks influenced by factors like sun exposure, skin type, and income.

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...

When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to better sensitivity than chest x-ray but does not lead to improved overall ...